Literature DB >> 1889309

Influence of human urine on the in vitro activity and postantibiotic effect of ciprofloxacin against Escherichia coli.

G G Zhanel1, J A Karlowsky, R J Davidson, D J Hoban.   

Abstract

The purpose of this investigation was to study the effects of human urine on the minimum inhibitory concentration (MIC) and the postantibiotic effect (PAE) of ciprofloxacin against Escherichia coli. MICs and the PAE were performed in Mueller-Hinton broth (MHB; pH 7.3 and 5.5) and in human urine (pH 5.5 and 7.3). In urine, pH 5.5, MICs increased 64-fold (from 0.016 to 1.024 micrograms/ml) and the PAE was abolished (from 101.6 to 3.7 min), when compared to MHB, pH 7.3. An acidic pH demonstrated the greatest effect on reduced susceptibility and PAE. Using ciprofloxacin concentrations adjusted for a higher MIC obtained in pH-adjusted urine and MHB, PAE values were similar for urine and MHB (approximately 280 min at 40 x MIC). This study demonstrated that the MIC and PAE of ciprofloxacin against E. coli are influenced by human urine and in particular its pH.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1889309     DOI: 10.1159/000238857

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  14 in total

1.  Subinhibitory antimicrobial concentrations: A review of in vitro and in vivo data.

Authors:  G G Zhanel; D J Hoban; G K Harding
Journal:  Can J Infect Dis       Date:  1992-07

2.  Postexposure factors influencing the duration of postantibiotic effect: significance of temperature, pH, cations, and oxygen tension.

Authors:  K Fuursted
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 3.  Protein binding of antimicrobials: methods for quantification and for investigation of its impact on bacterial killing.

Authors:  Jürgen Beer; Claudia Christina Wagner; Markus Zeitlinger
Journal:  AAPS J       Date:  2009-01-01       Impact factor: 4.009

4.  Urine bactericidal activity of pefloxacin versus norfloxacin in healthy female volunteers after a single 800-mg oral dose.

Authors:  H Hofbauer; K G Naber; M Kinzig-Schippers; F Sörgel; C Rustige-Wiedemann; B Wiedemann; A Reiz; M Kresken
Journal:  Infection       Date:  1997 Mar-Apr       Impact factor: 3.553

5.  In vitro postantibiotic effects following multiple exposures of cefotaxime, ciprofloxacin, and gentamicin against Escherichia coli in pooled human cerebrospinal fluid and Mueller-Hinton broth.

Authors:  J A Karlowsky; G G Zhanel; R J Davidson; S R Zieroth; D J Hoban
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

6.  Antibiotic activity in microbiological media versus that in human urine: comparison of ampicillin, ciprofloxacin, and trimethoprim-sulfamethoxazole.

Authors:  G R Drobot; J A Karlowsky; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

7.  Lipopolysaccharide directly alters renal tubule transport through distinct TLR4-dependent pathways in basolateral and apical membranes.

Authors:  David W Good; Thampi George; Bruns A Watts
Journal:  Am J Physiol Renal Physiol       Date:  2009-07-22

8.  Urinary Tract Physiological Conditions Promote Ciprofloxacin Resistance in Low-Level-Quinolone-Resistant Escherichia coli.

Authors:  Guillermo Martín-Gutiérrez; Jerónimo Rodríguez-Beltrán; José Manuel Rodríguez-Martínez; Coloma Costas; Javier Aznar; Álvaro Pascual; Jesús Blázquez
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

Review 9.  Urinary alkalisation for symptomatic uncomplicated urinary tract infection in women.

Authors:  Dermot B O'Kane; Sameer K Dave; Neel Gore; Farhaan Patel; Tammy C Hoffmann; Jeanne L Trill; Chris B Del Mar
Journal:  Cochrane Database Syst Rev       Date:  2016-04-19

Review 10.  Pharmacokinetic contributions to postantibiotic effects. Focus on aminoglycosides.

Authors:  G G Zhanel; W A Craig
Journal:  Clin Pharmacokinet       Date:  1994-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.